Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
-Primary and secondary endpoints of safety and immunogenicity met
-Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline
-Trial shows proof of concept for oral delivery of vaccines using Oravax technology
On October 7, Oramed announced that the oral COVID-19 vaccine developed by its subsidiary Oravax Medical had positive Phase I clinical data, meeting the primary and secondary endpoints of immunogenicity and safety.
This is a phase I clinical trial designed to evaluate the safety, tolerability, and immunogenicity of two concentrations of COVID-19 vaccine. A total of 24 healthy subjects were enrolled in a 2-dose regimen administered 21 days apart for a period of time. 24 weeks. The results showed that the oral COVID-19 vaccine could induce high titers of neutralizing antibodies in patients, and no safety issues including mild symptoms were observed.
The oral COVID-19 vaccine targets 3 major surface proteins of the COVID-19 virus, including the spike protein (Spike), the envelope protein (Membrane) and the membrane glycoprotein (Envelope). can provide protection.
Compared with injectable vaccines, oral vaccines have the following advantages, including reducing the use of refrigeration equipment during transportation and storage, expanding the range of people covered, and reducing the cost of training health care personnel.